{"paper_id":"ceae280b-be59-4676-961f-2506e4a04256","body_text":"PATHOGENETIC JUSTIFICATION OF THE USE OF PROBIOTICS IN PREPARATION PROGRAMS FOR ASSISTED REPRODUCTIVE TECHNOLOGIES IN WOMEN WITH ENDOMETRIOSIS BASED ON STUDYING INDICATORS OF THE LEVEL OF MESOTHELIN, mRNA IL1β, HMGB1, NLRP3-INFLAMMASOME\nDOI:\nhttps://doi.org/10.25040/ntsh2024.02.14Keywords:\ninfertility, endometriosis, endometrium, inflammasome, cytokines, lactobacilli, probiotics, assisted reproductive technologies.Abstract\nIntroduction. Treatment of infertility in women with endometriosis is an important and unsolved problem both in Ukraine and in the world. Along with this, in this cohort of patients, the efficiency of using assisted reproductive technologies (ART) remains low. The optimal approach in the program of preparation for ART of women with endometriosis is precisely probiotics with the content of lactobacilli as potential factors for reducing the production of provoking mediators of endometriosis and increasing the chances of a successful pregnancy.\nAim: To justify the feasibility of including probiotics in the program of preparation for intrauterine reproductive technologies in women with endometriosis-associated infertility.\nMethods and materials. The study included 88 women with endometriosis associated with infertility (the main group) and 68 women with tubal infertility (the control group). To analyze the expression of the NLPP3-inflammasome gene, HMGB1, IL1β and determine the relative normalized expression of NLRP3, HMGB1, IL1β mRNA, we used the polymerase chain reaction with reverse transcription in real-time (RT-PCR). The mesothelin level in blood serum was determined using the solid-phase enzyme-linked immunosorbent assay (ELISA).\nResults. In earlier stages of the work, the levels of pro-inflammatory markers such as the peritoneal damage marker mesothelin and the expression of NLRP3, IL-1β and HMGB1 in serum and locally in the peritoneal fluid were investigated in women with endometriosis associated with infertility, and results were obtained indicating a probable increase all the indicators listed above. In particular, a significantly higher average level of mesothelin concentration in blood plasma was observed in the main group compared to the control group (0,73±0,01 ng/ml and 0,49±0,01 ng/ml) (p<0,05); NLRP3-inflammasome mRNA expression level (44,43±3,72 c.u. and 0,85±0,03 c.u.) (p˂0,001); IL1β mRNA gene expression (26,47±0,01 c.u. and 0,45±0,01 c.u.) (p˂0,001) and HMGB1 mRNA expression (11,91±0,01 c.u. and 1,00±0,01 c.u.) (р˂0,001). When evaluating these parameters depending on the nature of infertility (primary or secondary), results were also obtained, which indicate that women with endometriosis and primary infertility had significantly higher levels of mesothelin, NLRP3, IL-1β, and HMGB1 inflammasome activity. In particular, the level of mesothelin in women of the main group with primary infertility was significantly higher compared to women with secondary infertility both in blood serum and peritoneal fluid, respectively (0,86±0,001 ng/ml and 0,69±0,001 ng/ ml) (p<0,01) to (0,67±0,001 ng/ml and 0,42±0,001 ng/ml) (p<0,001).\nConclusions.\n- The study confirmed that the mRNA expression levels of NLRP3, IL-1β, HMGB1 and mesothelin correlate with the severity of endometriosis and can be potential markers of disease progression. These molecules are promising targets for further therapeutic strategies in the treatment of infertility-associated endometriosis.\n- The study showed that the level of mesothelin in blood serum is 1,25 times higher in women with primary infertility than with secondary infertility and correlates with the severity of the disease, which indicates its possibility to be an independent marker for the diagnosis of endometriosis.\n- The literature data indicates that the use of probiotics in programs of preparation for assisted reproductive technologies (ART) in women with endometriosis is appropriate.\nDownloads\nReferences\nEndometriosis Associated Infertility: A Critical Review and Analysis on Etiopathogenesis and Therapeutic Approaches/ L.Filip et al.Medicina. 2020. Vol.56, no.9. P. 460. doi: https://doi.org/10.3390/medicina56090460\nEndometriosis-Associated Infertility / E.-S. Nada et al. Medicina Moderna - Modern Medicine. 2018. Vol.25, no.3. P.131–136. doi: https://doi.org/10.31689/rmm.2018.25.3.131\nDunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–12. doi: https://doi.org/10.1093/humrep/det457\nManagement of endometriosis-related infertility: Considerations and treatment options / D. Lee et al. Clinical and Experimental Reproductive Medicine. 2020. Vol. 47, no. 1. P.1–11. doi: https://doi.org/10.5653/cerm.2019.02971\nAta B., Telek SB Assisted reproductive technology for women with endometriosis, a clinically oriented review. Current Opinion in Obstetrics & Gynecology. 2021. Vol. 33, no. 3. P. 225–231. doi: https://doi.org/10.1097/gco.0000000000000710\nEndometriosis and Assisted Reproductive Technology: A Review Article / A. Ajayi et al. Medical & Clinical Reviews. 2017. Vol.03, no.01. doi: https://doi.org/10.21767/2471-299x.1000046\nNanda AKT, Banerjee P., Dutta M., Wangdi T., Sharma P., Chaudhury K., Jana SK Cytokines, Angiogenesis, and Extracellular Matrix Degradation are Augmented by Oxidative Stress in Endometriosis. Ann. Lab. Med. 2020;40:390–397. doi: https://doi.org/10.3343/alm.2020.40.5.390\nHypothetical roadmap towards endometriosis: prenatal endocrine-disrupting chemical pollutant exposure, anogenital distance, gut-genital microbiota and subclinical infections / P. García-Peñarrubia et al. Human Reproduction Update. 2020. Vol. 26, no. 2. P. 214–246. doi: https://doi.org/10.1093/humupd/dmz044\nGruber TM, Mechsner S. Pathogenesis of Endometriosis: The Origin of Pain and Subfertility. Cells. 2021. Vol.10, no.6. P.1381. doi: https://doi.org/10.3390/cells10061381\nZheng D., Liwinski T., Elinav E. Interaction between microbiota and immunity in health and disease. Cell Research. 2020. Vol. 30, no. 6. P.492–506. doi: https://doi.org/10.1038/s41422-020-0332-7\nGut microbiota and systemic immunity in health and disease / BC Lo et al. International Immunology. 2020. doi: https://doi.org/10.1093/intimm/dxaa079\nPunzón-Jiménez P., Labarta E. The impact of the female genital tract microbiome in women’s health and reproduction: a review. Journal of Assisted Reproduction and Genetics. 2021. doi: https://doi.org/10.1007/s10815-021-02247-5\nMicrobiota and Human Reproduction: The Case of Female Infertility / R. Tomaiuolo et al. High-Throughput. 2020. Vol.9, no.2. P.12. doi: https://doi.org/10.3390/ht9020012\nWee BA, Thomas M, Sweeney EL, Frentiu FD, Samios M, Ravel J, et al. A retrospective pilot study to determine whether the reproductive tract microbiota differs between women with a history of infertility and fertile women. Aust New Zeal J Obstet Gynaecol. 2018;58:341–348. doi: https://doi.org/10.1111/ajo.12754\nThe Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study / AR Perrotta et al. Reproductive Sciences. 2020. Vol. 27, no. 4. P.1064–1073. doi: https://doi.org/10.1007/s43032-019-00113-5\nSchoenmakers S., Laven J. The vaginal microbiome as a tool to predict IVF success. Current Opinion in Obstetrics and Gynecology. 2020. Vol. 32, no. 3. P.169–178. doi: https://doi.org/10.1097/gco.0000000000000626\nP–399 Temporal dynamics of an IVF/ICSI success prediction test based on the vaginal microbiome / A. Bielfeld et al. Human Reproduction. 2021. Vol. 36, Supplement_1. doi: https://doi.org/10.1093/humrep/deab130.398\nGarcía-Velasco JA, Budding D, Campe H, Malfertheiner SF, Hamamah S, Santjohanser C, et al. The reproductive microbiome – clinical practice recommendations for fertility specialists. Reprod BioMed Online. 2020;41:443–453. doi: https://doi.org/10.1016/j.rbmo.2020.06.014\nGiordano G., Ferioli E., Tafuni A. The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets. Cancers. 2022. Vol. 14, no. 9. P. 2283. doi: https://doi.org/10.3390/cancers14092283\nEpithelial-Mesenchymal Transition in Endometriosis–When Does It Happen? / L. Konrad et al. Journal of Clinical Medicine. 2020. Vol.9, no.6. P. 1915. doi: https://doi.org/10.3390/jcm9061915\nMesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma / SE Mutsaers et al. Current Opinion in Immunology. 2020. Vol. 64. P.88–109. doi: https://doi.org/10.1016/j.coi.2020.04.005\nMesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opinion on Biological Therapy. 2020. P. 1–14. doi: https://doi.org/10.1080/14712598.2021.1843628\nNLRP3 inflammasome-mediated Pyroptosis induces Notch signal activation in endometriosis angiogenesis / M. Zhang et al. Molecular and Cellular Endocrinology. 2023. P. 111952. doi: https://doi.org/10.1016/j.mce.2023.111952\nEffectiveness of NLRP3 Inhibitor as a Non-Hormonal Treatment for ovarian endometriosis / M. Murakami et al. Reproductive Biology and Endocrinology. 2022. Vol. 20, no. 1. doi: https://doi.org/10.1186/s12958-022-00924-3\nPotential of Lactobacillus acidophilus to modulate cytokine production by peripheral blood monocytes in patients with endometriosis / F. Mehdizadeh Sari et al. Iranian Journal of Microbiology. 2022. doi: https://doi.org/10.18502/ijm.v14i5.10965\nBaker JM, Chase DM, Herbst-Kralovetz MM. Uterine Microbiota: residents, tourists, or invaders? Front Immunol. 2018;9:1–16. doi: https://doi.org/10.3389/fimmu.2018.00208\nMoreno I, Franasiak JM. Endometrial microbiota — a new player in town. Fertil Steril. 2017;108:32–39. doi: https://doi.org/10.1016/j.fertnstert.2017.05.034\nSchoenmakers S, Laven J. The vaginal microbiome as a tool to predict IVF success. Curr Opin Obstet Gynecol. 2020;32:169–178. doi: https://doi.org/10.1097/GCO.0000000000000626\nGarcía-Velasco JA, Budding D, Campe H, Malfertheiner SF, Hamamah S, Santjohanser C, et al. The reproductive microbiome – clinical practice recommendations for fertility specialists. Reprod BioMed Online. 2020;41:443–453. doi: https://doi.org/10.1016/j.rbmo.2020.06.014\nSepideh Khodaverdi, Robabeh Mohammadbeigi, Mojdeh Khaledi et al., Beneficial Effects of Oral Lactobacillus on Pain Severity in Women Suffering from Endometriosis: A Pilot Placebo-Controlled Randomized Clinical Trial. 2019 Oct;13(3):178-183. doi: https://doi.org/10.22074/ijfs.2019.5584\nFranasiak JM, Werner MD, Juneau CR, Tao X, Landis J, Zhan Y, et al. Endometrial microbiome at the time of embryo transfer: next-generation sequencing of the 16S ribosomal subunit. J Assist Reprod Genet. 2016;33:129–136. doi: https://doi.org/10.1007/s10815-015-0614-z\nUterine deficiency of high-mobility group box-1 (HMGB1) protein causes implantation defects and adverse pregnancy outcomes / S. Aikawa et al. Cell Death & Differentiation. 2019. Vol. 27, no. 5. P. 1489–1504. doi: https://doi.org/10.1038/s41418-019-0429-z\nRegulatory mechanisms of HMGB1 and its receptors in polycystic ovary syndrome-driven gravid uterine inflammation / M. Hu et al. The FEBS Journal. 2022. doi: https://doi.org/10.1111/febs.16678\nKoval H, Chopiak V, Kamyshnyi A. mRNA tlr2 and tlr4 expression in the endometrium tissue in women with endometriosis associated with infertility. Georgian Med News. 2015 Jul-Aug;(244-245):7-11. PMID: 26177128.\nHarris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8:195–202. doi: https://doi.org/10.1038/nrrheum.2011.222\nDeng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity. 2018;49:740–53 e7. doi: https://doi.org/10.1016/j.immuni.2018.08.016","source_license":"CC0","license_restricted":false}